Specific Gene Mutations predict Success of glioblastoma immunotherapy

Testing for specific gene mutations may help to predict the patients with glioblastoma who will respond to immunotherapy, according to new research. The findings, published in the journal Nature Medicine also suggest a therapeutic target that could lead to improved immunotherapy in these patients.

Glioblastoma, the most common type of brain cancer, still lacks effective treatment. A type of immunotherapy called immune checkpoint inhibitors — which block the interaction between the PD-L1 protein in cancer cells and PD-1 in immune cells, boosting the anti-cancer response — has had success in diverse tumour types, such as Hodgkin’s lymphoma. In contrast, a Phase 3 trial of PD-1 blockers (NCT02017717) showed effectiveness in only 8% of patients with glioblastoma.

Responses to anti-PD1 therapies are linked to the infiltration of immune cells in the tumour microenvironment in various cancer types. The more cells within a tumour and the area surrounding it, the more likely a patient will respond to these treatments. However, glioblastoma is characterized by higher immunosuppression and a low rate of mutations, both of which are associated with poor responses to immune checkpoint inhibitors.


Other news

Upcoming Events


Technological University Dublin
3-4 September 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Lab Innovations

NEC, Birmingham (Hall 12)
30 & 31 October 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Jun 2019

Recent advances in cancer diagnostics

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.